![](https://thehcdata.com/wp-content/uploads/2024/03/pexels-anna-tarazevich-5910774-768x432.webp)
Noetik Secures $40M Series A to Advance Precision Cancer Therapies
Noetik, an AI-driven biotech firm using self-supervised machine learning and high-throughput spatial data to create cutting-edge cancer therapies, has announced the successful closure of an oversubscribed $40 million Series A…
![](https://thehcdata.com/wp-content/uploads/2023/05/pexels-andrea-piacquadio-3866322-768x384.webp)
Kiyatec Publishes Study on 3D Predict™ for High-Grade Glioma
Kiyatec, a leader in functional precision oncology, has announced the publication of a key study in Scientific Reports showcasing the benefits of the 3D Predict Glioma test for high-grade glioma…
![](https://thehcdata.com/wp-content/uploads/2024/08/pexels-karolina-grabowska-7269617-768x512.webp)
Jupiter Endovascular Gets FDA Nod for Vertex Pulmonary Embolectomy System Pivotal Study
Jupiter Endovascular, Inc., a medical tech innovator specializing in advanced endovascular procedures through Endoportal Control™, has received FDA approval for its Investigational Device Exemption application. This approval clears the way…
![](https://thehcdata.com/wp-content/uploads/2024/08/pexels-anastasia-shuraeva-9519530-768x512.webp)
CharmHealth Announces 2024 Innovation Challenge Winners
CharmHealth, a leader in healthcare technology solutions, has unveiled the winners of its 2024 Innovation Challenge. Entering its fourth year, the challenge aims to discover groundbreaking ideas poised to transform…
![](https://thehcdata.com/wp-content/uploads/2024/08/pexels-william-fortunato-6140714-768x512.webp)
Renata Medical’s Minima Growth Stent Gains FDA Approval for Aortic Coarctation and Pulmonary Artery Stenosis
Renata Medical has announced that the U.S. Food and Drug Administration (FDA) has approved its innovative Minima Growth Stent, designed specifically for neonates, infants, and young children. This unique stent…
![](https://thehcdata.com/wp-content/uploads/2023/05/pexels-werner-pfennig-6949978-768x384.webp)
ASM Announces Retirement of Founder and CEO Trung Phan
Applied Statistics & Management Inc. (ASM), a top provider of medical staff credentialing and privileging solutions, has announced the retirement of its founder, President, and CEO, Trung Phan. Trung Phan…
![](https://thehcdata.com/wp-content/uploads/2024/08/pexels-googledeepmind-17483867-1-768x512.webp)
RebrAIn Secures Second FDA Clearance for Enhancing Targeting in Neurosurgery
RebrAIn, a leader in precision neuro-surgery platforms, has secured its second FDA 510(k) clearance for its OptimMRI software. The latest version includes a machine learning model designed to aid in…
![](https://thehcdata.com/wp-content/uploads/2024/04/pexels-anna-tarazevich-8016901-768x432.webp)
Median Technologies’ eyonis™ LCS Lung Cancer Diagnostic Hits All Study Endpoints
Median Technologies (FR0011049824, ALMDT, PEA/PME scheme eligible) announced that its AI-powered diagnostic tool, eyonis™ LCS, met the primary and all secondary endpoints in the REALITY study, the first of two…
![](https://thehcdata.com/wp-content/uploads/2024/08/pexels-pixabay-247763-768x512.webp)
Kaneka Completes New Medical Device Plant in Hokkaido
Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Kazuhiko Fujii) (TOKYO: 4118) has opened its Tomatoh Manufacturing Site in the Tomakomai Tobu Area of Hokkaido, marking its seventh domestic business location and…
![](https://thehcdata.com/wp-content/uploads/2024/08/pexels-pixabay-265087-768x512.webp)
Alnylam Shares HELIOS-B Phase 3 Results on Vutrisiran for ATTR Amyloidosis at ESC Congress
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, has announced detailed results from the HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic for the treatment of…
![](https://thehcdata.com/wp-content/uploads/2024/08/pexels-cottonbro-5990031-768x512.webp)
Novotech Reaccredited as Employer of Choice for Gender Equality
Novotech, a global full-service clinical Contract Research Organization (CRO), is pleased to announce its renewal as a Workplace Gender Equality Agency (WGEA) Employer of Choice for Gender Equality (EOCGE) for…
![](https://thehcdata.com/wp-content/uploads/2023/05/pexels-andrea-piacquadio-3866322-768x384.webp)
Allurion Publishes Data Showing Continued Weight Loss After One Year on Its Program
Allurion Technologies, Inc. (NYSE: ALUR) has announced new study results showing an average weight reduction of 10.5% at four months, improving to 13.7% at one year with the Allurion Program.…